Drug intelligence / Profile preview

miricorilant + olanzapine

Development stage: Unknown
Lead developer: Corcept Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Miricorilant + olanzapine is a combination therapy consisting of miricorilant, a selective glucocorticoid receptor modulator, and olanzapine, an atypical antipsychotic. This combination is being investigated for its potential to mitigate the significant weight gain and metabolic disturbances commonly associated with olanzapine treatment. Clinical studies have shown that coadministration of miricorilant with olanzapine results in less weight gain and smaller increases in insulin, insulin resistance, triglycerides, and liver enzymes compared to olanzapine alone.

Other names: miricorilant + olanzapine

Targets

GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on miricorilant + olanzapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on miricorilant + olanzapine.

Explore the full profile